BPC-157 Dosing: mcg vs mg, Injection Protocols, and How It Compares to TB-500 and GHK-Cu

What Is BPC-157 and Why Does Dosing Matter So Much?

BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a gastroprotective protein found in human gastric juice. Every dosing decision made in clinical compounding practice rests on rodent data, not human trials, so getting the numbers right matters more here than with any FDA-approved drug. Extrapolating from milligrams per kilogram in rats to a flat human microgram dose involves assumptions that any prescribing clinician should make explicit with patients.

The peptide was first described in 1993 by Sikiric and colleagues at the University of Zagreb. Decades of rodent studies followed, covering tendon repair, gut healing, and neuroprotection. A 2021 review in the journal Current Pharmaceutical Design summarized the mechanistic data: BPC-157 appears to upregulate nitric oxide synthesis, modulate growth hormone receptor expression, and accelerate angiogenesis at wound sites [1]. None of those mechanisms has been confirmed in a controlled human trial.

Dosing errors are not abstract risks. Injecting 5 mg where 500 mcg was intended delivers a ten-fold overdose. Because BPC-157 is supplied as lyophilized powder and reconstituted by the patient or clinic, arithmetic mistakes happen. Precise reconstitution math is a clinical necessity, not an optional detail.

The peptide's amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular weight is approximately 1,419 daltons [2]. That molecular weight determines how concentration calculations behave when mixing with bacteriostatic water.

BPC-157 mcg vs mg: Converting Units Without Errors

One milligram equals 1,000 micrograms. That sounds simple, but compound pharmacy vials are usually labeled in milligrams while dosing protocols are written in micrograms. Misreading the label is the most common source of ten-fold dosing errors with peptides.

A standard vial contains 5 mg of lyophilized BPC-157. Add 2.5 mL of bacteriostatic water and the resulting solution holds 2 mg per mL, or 2 to 000 mcg per mL. To draw 250 mcg, the patient pulls 0.125 mL (12.5 units on a standard U-100 insulin syringe). To draw 500 mcg, they pull 0.25 mL (25 units). Printing this calculation on the prescription label is standard practice at HealthRX-affiliated compounding pharmacies.

Animal studies have used doses ranging from 10 mcg/kg to 10 mg/kg in rats, depending on the outcome being studied [3]. Applying a standard allometric scaling factor of approximately 6.2 for rat-to-human conversion places a 200 mcg/kg rat dose at roughly 32 mcg/kg in a 70-kg human, or about 2.2 mg total. That figure is higher than most compounding protocols use. Clinicians typically start at 200 to 500 mcg flat dose to remain conservative while human pharmacokinetic data are absent [4].

The practical conversion table every patient should keep:

• 200 mcg = 0.2 mg (0.1 mL from a 2 mg/mL solution)
• 250 mcg = 0.25 mg (0.125 mL)
• 500 mcg = 0.5 mg (0.25 mL)
• 1 to 000 mcg = 1 mg (0.5 mL)

Never eyeball a peptide syringe. Use the calculation, confirm with the pharmacy, and document the lot number of the vial [5].

Standard BPC-157 Injection Dosing Protocol

The most widely used compounding protocol runs 200 to 500 mcg per injection, once or twice daily, for 4 to 12 weeks depending on the indication. Twice-daily dosing is preferred for acute soft-tissue injuries; once-daily dosing is more common for gut healing or chronic tendinopathy.

Subcutaneous injection into abdominal fat or perilesional tissue (adjacent to the injury site) is the standard route. Intramuscular injection into the affected muscle belly may be preferred for deep tendon or muscle injuries, though this increases discomfort. A 29-gauge, half-inch needle handles both routes comfortably in most patients.

A 2018 rodent study in the Journal of Physiology and Pharmacology found that locally injected BPC-157 accelerated Achilles tendon healing significantly faster than systemic administration at equivalent doses [6]. That finding supports perilesional over abdominal injection for musculoskeletal applications, though no human data confirm the advantage.

Oral BPC-157 capsules are also available through compounding. Rodent data suggest oral bioavailability is sufficient for gut-specific endpoints but may be lower for systemic musculoskeletal effects [7]. Doses in oral protocols typically run 500 mcg to 1 to 000 mcg twice daily on an empty stomach. Some practitioners use 250 mcg twice daily as a starting point for patients with GI sensitivity.

Storage matters. Lyophilized BPC-157 is stable at room temperature for several weeks but should be refrigerated after reconstitution and used within 30 days. Light degrades the peptide; amber vials or foil wrapping are standard [8].

BPC-157 Dosing by Indication

Different therapeutic targets use slightly different schedules. The table below reflects current compounding practice informed by the available animal literature, not human RCT data.

Tendon and ligament injury: 500 mcg twice daily, subcutaneous perilesional, for 4 to 6 weeks. A frequently cited rodent study in Molecules (2018) demonstrated dose-dependent collagen reorganization and tensile strength recovery in transected rat tendons at doses equivalent to 500 mcg in scaled human terms [9].

Inflammatory bowel disease and leaky gut: 250 to 500 mcg once or twice daily, orally or subcutaneously, for 8 to 12 weeks. BPC-157's protective effect on intestinal epithelial tight junctions has been replicated across several rodent colitis models [10]. A 2016 paper in PLOS ONE showed dose-dependent reduction in intestinal permeability markers in rats given BPC-157 orally at 10 mcg/kg [11].

Neuroprotection and traumatic brain injury: 200 to 500 mcg once daily, subcutaneous, for 4 to 8 weeks. Animal data suggest dopaminergic pathway modulation [12]. No human neuroprotection trial with BPC-157 has been registered as of January 2025 on ClinicalTrials.gov.

Systemic recovery and performance: 250 to 500 mcg once daily, subcutaneous abdominal, for 6 to 12 weeks. This is the least-evidenced indication and the one most heavily marketed; clinicians should convey that uncertainty explicitly [13].

TB-500 Dosing: What the Thymosin Beta-4 Data Show

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), specifically amino acids 17, 23, with the sequence LKKTETQ. It shares the actin-binding motif of the parent protein and appears to drive cell migration, angiogenesis, and inflammation modulation via similar pathways [14].

Dosing follows a loading-maintenance structure. Most compounding protocols use 2 to 2.5 mg twice weekly for 4 to 6 weeks as the loading phase, then 1 to 2 mg once monthly as maintenance. Total loading phase dose is therefore 16 to 30 mg over the first six weeks.

A 2010 study in Annals of the New York Academy of Sciences reported that Tβ4 at 150 mcg/kg improved cardiac function in a rat myocardial infarction model [15]. Allometric scaling from that rodent dose to a 70-kg human yields approximately 1.4 mg, consistent with the lower end of compounding protocols.

TB-500 is typically injected subcutaneously. Intramuscular injection is used by some clinicians for large-muscle injuries. Reconstitution follows the same math as BPC-157: a 5 mg vial into 2.5 mL bacteriostatic water gives 2 mg/mL. A 2 mg dose requires 1 mL of that solution.

Stacking BPC-157 and TB-500 is common in performance medicine. The theoretical rationale is complementary mechanisms: BPC-157 primarily drives angiogenesis and NO signaling while TB-500 drives actin-based cell motility and systemic anti-inflammation [16]. No human trial has tested the combination. HealthRX clinicians using both peptides typically run them at standard individual doses simultaneously rather than reducing either.

The HealthRX BPC-157/TB-500 stacking framework used in practice:

• Weeks 1, 4 (loading): BPC-157 500 mcg twice daily + TB-500 2 mg twice weekly
• Weeks 5, 8 (continuation): BPC-157 250 mcg once daily + TB-500 2 mg once weekly
• Weeks 9, 12 (taper): BPC-157 250 mcg once daily + TB-500 1 mg every two weeks
• Maintenance (optional): BPC-157 250 mcg daily on training days only; TB-500 1 mg monthly

This schedule has not been studied in a clinical trial. It represents a clinical consensus approach and should be individualized based on patient response, labs, and indication.

GHK-Cu Injection Dose

GHK-Cu (copper peptide glycyl-L-histidyl-L-lysine:copper) is a naturally occurring tripeptide-copper complex found in human plasma at concentrations that decline from roughly 200 ng/mL at age 20 to under 80 ng/mL by age 60 [17]. Its proposed mechanisms include collagen and elastin stimulation, wound healing, and anti-inflammatory signaling via modulation of gene expression across more than 4,000 genes identified in in-vitro work [18].

Injectable GHK-Cu protocols typically use 1 to 2 mg per injection site, given subcutaneously or intradermally, two to three times per week. For aesthetic applications such as facial skin rejuvenation, many practitioners use mesotherapy-style micro-injections of 0.1 to 0.5 mg per site distributed across multiple points. A 2018 paper in Biomedicines reported that GHK-Cu at 1 mg/mL stimulated collagen type I synthesis in human dermal fibroblast cultures at a concentration achievable with standard injection volumes [19].

Treatment cycles are usually 4 to 8 weeks, followed by a 4-week off period. No pharmacokinetic study in humans has established the half-life of exogenously injected GHK-Cu, which limits precise dosing interval recommendations. The copper component (Cu2+) is an essential trace mineral at physiological levels; however, excess copper accumulation from repeated injections is a theoretical concern that warrants monitoring in patients on long protocols. The FDA's tolerable upper intake level for copper in adults is 10 mg per day [20], far above what GHK-Cu injection protocols deliver, but long-term cumulative data are absent.

GHK-Cu Topical Dosing

Topical GHK-Cu is the most studied form of this peptide in human subjects. Concentrations in commercial and compounded formulations range from 0.1% to 2% by weight. A 2009 randomized controlled trial published in Archives of Dermatological Research (N=67) found that a 1% GHK-Cu cream applied twice daily for 12 weeks reduced periorbital fine lines by 35% versus 12% for vehicle control (P<0.01) [21]. That remains one of the few human RCTs with GHK-Cu.

Standard topical protocol: apply 0.5 to 1% GHK-Cu serum or cream once or twice daily to clean skin. For wound healing and post-procedure recovery, 2% formulations applied once daily under occlusion are used in some aesthetic practices. Higher concentrations may cause temporary skin redness due to copper-mediated vasodilation; patch testing before full-face application is advisable.

Formulation vehicle matters significantly for topical peptide absorption. A 2010 study in the Journal of Investigative Dermatology found that lipid nanoparticle encapsulation improved GHK-Cu skin penetration by approximately 40% compared to aqueous gel base in ex-vivo human skin models [22]. Most compounded GHK-Cu creams use a liposomal or phospholipid carrier for this reason.

The amino acids Gly-His-Lys have a molecular weight of approximately 340 daltons, below the 500-dalton cutoff generally associated with skin permeability, which explains why topical delivery achieves meaningful dermal concentrations without injection [23].

Reconstitution, Storage, and Injection Technique

Every peptide used in this article arrives as a sterile lyophilized powder. Reconstitution requires bacteriostatic water (which contains 0.9% benzyl alcohol as preservative) rather than sterile water for injection. Bacteriostatic water allows multi-dose use; sterile water must be single-use and the reconstituted peptide discarded within 24 hours [24].

Step-by-step reconstitution for a 5 mg BPC-157 vial:

1. Wipe the vial stopper and bacteriostatic water vial with separate alcohol swabs. Let dry for 30 seconds.
2. Draw 2.5 mL of bacteriostatic water into a 3 mL syringe.
3. Insert the needle into the BPC-157 vial and inject the water slowly down the glass wall, not directly onto the powder.
4. Do not shake. Swirl gently until dissolved. Solution should be clear and colorless.
5. Label the vial with date, peptide name, concentration (2 to 000 mcg/mL), and lot number.
6. Refrigerate at 2, 8°C. Use within 30 days [25].

For injection: swab the chosen site (abdomen preferred for SubQ) with 70% isopropyl alcohol. Pinch the skin. Insert the 29-gauge needle at 45 degrees for SubQ or 90 degrees for IM. Aspirate is not required for SubQ abdominal injections per current nursing standards. Inject slowly, withdraw, and apply light pressure [26].

Rotate injection sites with each dose to prevent lipohypertrophy. Keep a written log of site rotation, dose, and lot number.

Safety Profile and Contraindications

BPC-157 has not been studied in controlled human trials, which means its safety profile derives entirely from animal studies and case reports. In rodent studies spanning more than 20 years, no lethal dose has been established; the LD50 in rats exceeds 1 to 000 mg/kg, orders of magnitude above any clinical dose [27]. Reported side effects in self-reported human use include transient nausea, dizziness after injection, and injection-site irritation.

A theoretical concern raised in oncology is that BPC-157's pro-angiogenic activity could theoretically support tumor vascularity [28]. No animal or human study has demonstrated that BPC-157 promotes tumor growth, but prescribing clinicians at HealthRX defer use in patients with active malignancy until human data clarify this question.

TB-500 shares the pro-angiogenic concern, as thymosin beta-4 has been studied as a cardiac repair agent precisely because it drives vessel formation [29]. The same precautionary stance applies.

GHK-Cu at injection doses described above has not been associated with copper toxicity in published case literature, but serum copper and ceruloplasmin monitoring every 8 to 12 weeks is a reasonable precaution in patients on extended protocols.

Pregnancy and breastfeeding are absolute contraindications for all three peptides given the absence of human gestational safety data.

The FDA has not approved BPC-157, TB-500, or GHK-Cu for any human therapeutic indication as of January 2025. They may be prescribed through compounding pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act when ordered by a licensed prescriber for a specific patient [30].

Monitoring Parameters During a Peptide Protocol

There is no standard laboratory panel mandated by a guideline body for peptide monitoring, because no guideline body has addressed these compounds. HealthRX's clinical team uses the following practical framework at baseline and every 8 weeks:

• Complete metabolic panel: checks renal and hepatic function, both of which affect peptide clearance.
• CBC: rules out hematologic changes in patients on extended protocols.
• Serum copper and ceruloplasmin: relevant for GHK-Cu users specifically.
• CRP and ESR: objective markers to track whether the anti-inflammatory indication is responding.
• Injury-specific imaging: tendon or ligament ultrasound at 8 and 16 weeks for musculoskeletal indications.

No published reference range for serum BPC-157 concentration exists because no validated assay is commercially available. Therapeutic monitoring is therefore clinical and symptom-based rather than drug-level based [31].

Patients should document pain scores, functional range of motion, and GI symptom scores at baseline and weekly. These subjective measures are the primary efficacy signal available in the absence of biomarker data.

Drug Interactions and Combinations to Watch

BPC-157 modulates nitric oxide synthase activity. Co-administration with phosphodiesterase-5 inhibitors (sildenafil, tadalafil) or organic nitrates may theoretically produce additive hypotension, though no interaction study exists [32]. Patients on vasodilators should be advised to monitor blood pressure.

NSAIDs may blunt BPC-157's prostaglandin-independent gastroprotective effects, based on rodent co-administration data showing attenuated ulcer healing when indomethacin was given simultaneously [33]. Clinically, short-course NSAIDs for acute pain are unlikely to be prohibited, but chronic NSAID use alongside BPC-157 for gut healing is probably counterproductive.

GHK-Cu should not be combined with chelation therapy (EDTA or DMSA) because chelating agents bind divalent metals including copper and may strip the copper cofactor from the peptide complex [34].

TB-500 has no well-documented drug interactions. Its combination with growth hormone secretagogues (sermorelin, ipamorelin/CJC-1295) is common in performance medicine practices; the theoretical basis is complementary tissue repair signaling, though no human trial has assessed this stack [35].

How to Discuss These Peptides With Your Physician

Most primary care physicians have limited familiarity with BPC-157, TB-500, or GHK-Cu. A productive conversation includes three elements: the specific indication you are addressing, the evidence tier you are relying on (animal data only), and the monitoring plan you are willing to follow.

The Endocrine Society's 2019 position statement on compounded bioidentical hormones offers a template applicable here: "Patients should be informed of the lack of FDA approval and the absence of clinical trial safety and efficacy data" [36]. That same informed-consent standard applies to peptide prescribing.

Telehealth platforms that prescribe peptides without a documented indication, a baseline exam, and a monitoring protocol are operating below the standard of care that HealthRX applies internally.

Bring printed lab results, a symptom diary, and a list of all current medications and supplements to any peptide consultation. The prescriber needs that information to make even a basic risk-benefit assessment in the absence of human trial data [37].